Roth Capital Previews Preclinical PRESERVATION-1 Data; Affirms BioLineRx (BLRX) at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
UPDATE: JMP Securities Starts BioLineRx (BLRX) at Market Outperform
June 22, 2015 7:47 AM EDT(Updated - June 22, 2015 8:58 AM EDT)
JMP Securities initiated coverage on BioLineRx (NASDAQ: BLRX) with a Market Outperform rating and a price target of $5.00. Analyst Michael King Jr thinks investors are undervaluating the company's pipeline, given four of six assets are in phase II... More
